MP01-01: Exime&[reg] urethral stent implantation (EUSI) as initial treatment for patients presenting with acute urinary retention (AUR) for the first time as a result of BPH

Nordine Amara*, leffrinckoucke, France, Tarek Al Youssef, jordan massa, elias elkhouri, Dunkerque, France, belur patel, temple, TX

Introduction: Acute urinary retention (AUR) is a painful and distressing condition which is associated with significant morbidity requiring hospitalization, catheterization and often surgery. AUR often develops from benign prostatic hyperplasia (BPH) and its incidence increases with age. Management will often necessitates the insertion of a urinary catheter.  We studied the efficacy of Exime® urethral stent implantation (EUSI) as initial treatment for patients presenting with acute urinary retention (AUR) for the first time as a result of BPH.

Methods: From January 2019 to January 2022 61 BPH patients underwent EUSI. The patients were aged 52-91 years old (mean 67.3 years), with a prostate volume of 30-120ml (mean 67ml) and IPSS score of 24 ± 5.7. The same technique for insertion of EUSI under local anesthesia was used for each patient.

Results: Of the 61 patients 55 (90%) achieved spontaneous urination immediately after procedure; 3 patients (4.9%) developed urinary infection symptoms; 3 patients (4,9%) experienced bladder clot retention. No urethral injury an no false route were noted.

Conclusions: EUSI, with its advantages of simple operation, high safety, definite effectiveness, is a new effective option for the treatment of AUR due to  BPH. As more minimally invasive, office-based technologies emerge, physician and patients will have the ability to choose a treatment that is more catered to patient expectations. Further studies are needed to better define its place in this setting.

Source of Funding: none